CORRECTED: PTAB Axes Patent After Purdue Ch. 11 Delay

By Andrew Karpan (November 22, 2021, 9:07 PM EST) -- The Patent Trial and Appeal Board has invalidated a Purdue Pharma patent for an opioid with an abuse deterrent, faulting the patent description and rejecting Purdue's argument that the board took too long to issue a decision.

Friday's ruling from the patent board came more than two years after a decision on the post-grant petition from Collegium Pharmaceutical was originally due. The delay was caused by Purdue's filing for bankruptcy in September 2019 in an effort to hold back the wave of lawsuits the company faced over its role marketing drugs in the opioid crisis.

The Chapter 11 filing put a plug...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!